Studies

The Oral Diversity Study

Aims:

To investigate how

  1. common oral HPV infection is in Australia and if oral HPV infection is linked to lifestyle or sexual behaviour.
  2. the vaccines against HPV (Gardasil® of Cervarix®) affects oral HPV infection.

Participation involves:

We will ask you to:

  1. Complete a brief survey form (this takes about 10 minutes and includes questions about your age, lifestyle and lifetime number of kissing and sexual partners)
  2. Donate a saliva sample that will be tested for the presence of HPV
  3. Consider to allow the study team to access my data about HPV vaccination in the Australian Immunisation Register.

If you would like to take part in the study we will post a study pack to you. The study pack contains an information sheet, consent forms, questionnaire (4 pages; ~10 min to complete), a saliva collection kit, biohazard bag to return the saliva sample in and a reply paid envelope.

Eligibility criteria:

Eligibility: Individuals aged 18 to 70 years.

Exclusion criteria: Ever been diagnosed with oropharyngeal cancer.

Description of the Study

During the last decade, there has been a major increase in the number of mouth and throat cancers in younger non-smokers that are related to human papillomavirus (HPV). HPV is the major cause of cervical cancer and the cause of 5% of all human cancers worldwide. While other cancers related to smoking are decreasing, cancers of the mouth and throat are increasing in incidence and this is believed to be due to increasing oral HPV infections.

Despite the major increase of HPV-related mouth and throat cancers, remarkably little is known about oral HPV infection. It is not even known how common oral HPV infection is in the general population.

It is also important to map which HPV types exist in the mouth and throat for future prevention of mouth and throat cancers through vaccination.

The purpose of this research project is to investigate how common oral HPV infection is in Australia and if oral HPV infection is linked to lifestyle or sexual behaviour. We are also interested in how the vaccines against HPV (Gardasil® of Cervarix®) affects oral HPV infection.

QIMR-HREC Approval Reference: P3538

Open Date: October 2020

Recruitment Status: OPEN 

Close Date: ONGOING

STUDY CONTACT DETAILS

Coordinator/s: Coordinating Principal Investigator: Associate Professor Annika Antonsson

T 07 3845 3542
E Oral.Diversity@qimrberghofer.edu.au
A QIMR Berghofer Medical Research Institute
Locked Bag 2000, Royal Brisbane Hospital, Herston, QLD,
4029, Australia.

For more information and to participate now, please email us: Oral.Diversity@qimrberghofer.edu.au